top of page

GDC-6036 - new drug for KRAS G12C+ cancers looking promising in preclinical studies

GDC-6036 - new drug for KRAS G12C+ cancers looking promising in preclinical studies. More potent than sotorasib & adagrasib. Clinical trial will be crucial in determining applicability in clinical setting/treatment sequencing for KRAS pG12C+ tumors


https://www.lungevity.org/

Single post: Blog_Single_Post_Widget
bottom of page